The most common types of primary headaches are cluster headaches which are known as trigeminal autonomic cephalgia. These cluster headaches can come every other day, one to eight times a day like other trigeminal autonomic cephalgia’s. Approximately, they commonly occur at same time of the day, most often at night. Many patients are periodic, with daily attacks for weeks to months, followed by remission for months to years. As cluster headaches are rare, they can be significantly exhausting, leading to a highly reduction in quality of life. The prevalence and incidence of cluster headaches are rising, which is augmenting the demand for effective treatments which is a key driving factor. Moreover, currently, there are no FDA-approved medications especially for the cluster headaches treatment. This implies that there is a major unmet requirement for effective treatments for this condition, which is augmenting the research and development efforts in this area. On the other hand, the factors limiting the cluster headache market growth are adverse effects of cluster headache drugs.

The global Cluster Headache Market is projected to reach US$ 522.98 million by 2028, growing at a CAGR of 3.9%.

The Cluster Headache Market has been segmented below:

Cluster Headache Market by Drug class    

• Ergot derivatives
• Calcium channel blockers
• Triptans
• Others

Cluster Headache Market by Distribution channel  

• Hospital pharmacies
• Drug stores and retail pharmacies
• Others

Cluster Headache Market by Type  

• Episodic
• Chronic 

Cluster Headache Market by Geography    

• North America
• Europe
• Asia Pacific
• Rest of the World

The cluster headache market by drug class is divided into Ergot derivatives, Calcium channel blockers, Triptans and Others. The triptans segment holds the maximum share in the market growth. The maximum share of the segment is owing to the first line treatment for cluster headache. Triptans are a class, or group, of medicines which can stop migraine episodes. These drugs work to decrease symptoms by building enlarged blood arteries in the brain brought on by migraine attacks. Also, they are present in various dose formulations.

On the basis of distribution channel, the cluster headache market is categorized into Hospital pharmacies, Drug stores and retail pharmacies and Others. The drug stores and retail pharmacies segment held the maximum share in the market growth. This is due to the increase in consumer preference for retail pharmacies, which provide advice on drugs and their use throughout treatment periods and they also provide affordable prices.

As per the type the cluster headache market is bifurcated into Episodic and Chronic. The episodic segment accounted for the major share in the cluster headache market. The major share is owing to the surge in number of people suffering from episodic attack and increase in regulatory approval of drugs indicated for episodic cluster headache.

The regional market is divided into North America, Europe, Asia Pacific and rest of the world. North America region has occupied the major share in the cluster headache market growth due to the factors such as surge in prevalence of cluster headache cases, incidence of advanced healthcare infrastructure and rise in number of key players providing new therapeutics.

Several organizations coupled with governments across the world are counseling people about the headache disorders. E-commerce (electronic commerce) has become a significant tool for small and large businesses globally, owing to increase in preference of consumers for online shopping over conventional purchasing methods. Several animations through health apps to educate people about headache disorders and usage of medications have lead towards the growth of global cluster headache market.

Key players operating in the cluster headache market include Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., FRESENIUS SE & Co. KGaA, GlaxoSmithKline plc, Pfizer Inc., Arrotex Australia Group, Grunenthal, and Novartis AG.

As a result, the there is a major unmet requirement for effective treatments for cluster headaches. Henceforth, there is a rising focus on the development of new treatments, such as new pharmacological agents and neuromodulation devices which is projected to augment innovation in the market.   

• Complete information on factors is provided which will propel cluster headache market growth in the forecast period.
• This report gives the exact estimation of the market size and its contribution to the parent market along with the precise estimation on upcoming trends and shifts in consumer behavior.
• This research provides growth analysis of the cluster headache market among regions such as North America, Europe, Asia Pacific and rest of the world.
• This report further provides comprehensive details of factors which will challenge the growth of cluster headache market players.